Damora Therapeutics, Inc. — Form 10-Q
Filed November 4, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Damora Therapeutics established a 2026 Equity Incentive Plan authorizing restricted stock unit (RSU) awards to employees and service providers. The filing provides the standard grant notice and terms template but does not disclose specific participant names, grant dates, RSU quantities, or vesting commencement dates—these are shown as blank placeholders [●]. RSUs vest 25% annually over four years upon continued employment, with settlement in ordinary shares within 60 days of vesting.
Why this rating
Boilerplate equity plan adoption is routine corporate governance. No specific grants disclosed; template only. Immaterial relative to $4.4M market cap absent actual award data.
See more from November 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.